Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21343563 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: monoclonal antibody 3F8;   Biological: sargramostim

Indicates status has not been verified in more than two years